Kim, Victoria M.
Blair, Alex B.
Lauer, Peter
Foley, Kelly
Che, Xu
Soares, Kevin
Xia, Tao
Muth, Stephen T.
Kleponis, Jennifer
Armstrong, Todd D.
Wolfgang, Christopher L.
Jaffee, Elizabeth M.
Brockstedt, Dirk
Zheng, Lei http://orcid.org/0000-0003-4163-2541
Funding for this research was provided by:
National Institutes of Health (R01 CA169702, R01 CA197296, T32 CA126607)
National Institutes of Health (K23 CA148964, T32 CA126607)
Skip Viragh Foundation (., .)
Lefkofsky Family Foundation (.)
National Cancer Institute Specialized Programs of Research Excellence in Gastrointestinal Cancers (P50 CA062924)
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973, P30 CA006973)
Lustgarten Foundation (.)
Article History
Received: 10 January 2019
Accepted: 23 April 2019
First Online: 22 May 2019
Ethics approval and consent to participate
: All animal care and experiments were performed in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines.
: Not applicable.
: L.Z. receives grant supports from Bristol-Meyer Squibb, Merck, iTeos, Amgen, Gradalis, and Halozyme, and receives the royalty for licensing GVAX to Aduro Biotech. L.Z. is a consultant/Advisory Board Member at Sound Biologics, Biosion, Fosun Biopharmaceutical, Mingrui, Oncorus, Alphamab, Merck, and AstroZeneca. L.Z. is a sharefolder of Alphamab and Minguri. E.M.J. receives the royalty for licensing GVAX to Aduro Biotech. E.M.J receives grant support from Bristol-Myer Squibb, Amgem and Hertix. E.M.J is a consultant/Advisory Board Member at CSTONE, Genocea, Dragonfly and Adaptive Biotech. DB and PL are former employees of Aduro Biotech and current shareholders.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.